Ignite Creation Date:
2024-05-05 @ 12:00 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00203190
Status:
TERMINATED
Last Update Posted:
2009-01-23
First Post:
2005-09-12
Brief Title:
A Double-Blind Placebo-Controlled Study Examining the Use of Topiramate in the Treatment of Cluster Headache
Sponsor:
Thomas Jefferson University
Organization:
Thomas Jefferson University
Study Overview
Official Title:
A Single-Center Randomized Double-Blind Placebo Controlled Trial Examining the Safety and Efficacy of Topiramate in the Treatment of Subjects With Episodic or Chronic Cluster Headache
Status:
TERMINATED
Status Verified Date:
2009-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Topiramate is a medication that has been approved by the Food and Drug Administration FDA for the treatment of patients with seizures The trade name for this drug is Topamax Topiramate has not been approved by the FDA for the treatment of cluster headache and is experimental for the purposes of this research study If a subject participates in this study heshe will increase hisher dose of topiramate rapidly in the first few weeks to try to stop the cluster attacks and then will continue on a maintenance dose of topiramate in order to determine if it can prevent attacks from occurring during that cluster period We believe that this will lead not only to a faster but a more complete remission of the cluster period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 080-19000-H56501 | None | None | None |